Alvotech upgraded to “buy” by Deutsche Bank as biosimilar launches boost outlook
PositiveFinancial Markets
Alvotech has received an upgrade to a 'buy' rating from Deutsche Bank, reflecting a positive outlook driven by the successful launch of its biosimilars. This upgrade is significant as it indicates investor confidence in Alvotech's growth potential and the increasing demand for biosimilars in the healthcare market, which can lead to more affordable treatment options for patients.
— Curated by the World Pulse Now AI Editorial System